On Chip Bioelectric Impedance Spectroscopy Reveals the Effect of P-Glycoprotein Efflux Pumps on the Paracellular Impedance of Tight Junctions at the Blood-Brain Barrier

被引:7
作者
Kraya, Ramsey [1 ,2 ]
Komin, Alexander [2 ,3 ]
Searson, Peter [2 ,3 ]
机构
[1] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Inst Nanobiotechnol, Baltimore, MD 21218 USA
[3] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA
基金
美国国家卫生研究院;
关键词
Bioimpedance; cells (biology); drug delivery; TYROSINE PHOSPHATASE INHIBITION; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; TUMOR-CELLS; OCCLUDIN; PHOSPHORYLATION; PERMEABILITY; TRANSPORT; PATHWAYS; BILAYERS;
D O I
10.1109/TNB.2016.2604322
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Bioelectric impedance spectroscopy was used to elucidate the influence of P-gp efflux pumps on the kinetics of tight junction down-regulation in confluent monolayers of Madine Darby Canine Kidney Epithelial Cells (MDCK) following administration of phenylarsine oxide (PAO), a molecule that inhibits protein tyrosine phosphatases (PTP) and induces matrix metalloproteinase activity. Matrix metalloproteinases (MMPs) and phosphatase inhibitors induce modification of occludin tight junction proteins critical for the proper function of the blood-brain barrier. The addition of PAO to MDCKII cell lines resulted in a dramatic decrease in monolayer resistance. In contrast, MDCKII-MDR1 cells transfected with the MDR1 gene treated with PAO showed an initial decrease in monolayer resistance followed by a partial recovery and subsequent decrease. This resistance decay reversal was suppressed with the addition of the P-glycoprotein (P-gp) pump inhibitor elacridar, and is attributed to PAO efflux. These results illustrate impedance spectroscopy can be used to characterize the competing kinetics of efflux and down-regulation of tight junctions. In addition, the resistance decay reversal effect can be used to evaluate P-gp pump inhibitor efficacy.
引用
收藏
页码:697 / 703
页数:7
相关论文
共 50 条
[41]   Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-β in a Mouse Model of Alzheimer's Disease [J].
Hartz, Anika M. S. ;
Miller, David S. ;
Bauer, Bjoern .
MOLECULAR PHARMACOLOGY, 2010, 77 (05) :715-723
[42]   Proteasome inhibition protects blood-brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer's disease model [J].
Vulin, Milica ;
Zhong, Yu ;
Maloney, Bryan J. ;
Bauer, Bjoern ;
Hartz, Anika M. S. .
FLUIDS AND BARRIERS OF THE CNS, 2023, 20 (01)
[43]   Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier [J].
de Klerk, Onno L. ;
Willemsen, Antoon T. M. ;
Roosink, Meyke ;
Bartels, Anna L. ;
Hendrikse, N. Harry ;
Bosker, Fokko J. ;
den Boer, Johan A. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2009, 12 (07) :895-904
[44]   Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling [J].
Riganti, Chiara ;
Salaroglio, Iris C. ;
Pinzon-Daza, Martha L. ;
Caldera, Valentina ;
Campia, Ivana ;
Kopecka, Joanna ;
Mellai, Marta ;
Annovazzi, Laura ;
Couraud, Pierre-Olivier ;
Bosia, Amalia ;
Ghigo, Dario ;
Schiffer, Davide .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2014, 71 (03) :499-516
[45]   The expression of P-glycoprotein is increased in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model [J].
Ueno, M. ;
Nakagawa, T. ;
Huang, C. -I. ;
Ueki, M. ;
Kusaka, T. ;
Hosomi, N. ;
Kanenishi, K. ;
Onodera, M. ;
Wu, B. ;
Sakamoto, H. .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2009, 35 (02) :147-155
[46]   P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdialysis and mathematical modeling [J].
De Lange, E. C. M. ;
van der Berg, D. J. ;
Bellanti, F. ;
Voskuyl, R. A. ;
Syvanen, S. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 124 :61-70
[47]   Physiology and Pathophysiology of the Blood-Brain Barrier: P-Glycoprotein and Occludin Trafficking as Therapeutic Targets to Optimize Central Nervous System Drug Delivery [J].
McCaffrey, Gwen ;
Davis, Thomas P. .
JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (08) :1131-1140
[48]   Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11C]verapamil in elderly vs. young subjects [J].
Bauer, Martin ;
Wulkersdorfer, Beatrix ;
Karch, Rudolf ;
Philippe, Cecile ;
Jaeger, Walter ;
Stanek, Johann ;
Wadsak, Wolfgang ;
Hacker, Marcus ;
Zeitlinger, Markus ;
Langer, Oliver .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (09) :1991-1999
[49]   Blood-brain barrier cell line PBMEC/C1-2 possesses functionally active P-glycoprotein [J].
Neuhaus, Winfried ;
Stessl, Martina ;
Strizsik, Elisabeth ;
Bennani-Baiti, Barbara ;
Wirth, Michael ;
Toegel, Stefan ;
Modha, Maaya ;
Winkler, Johannes ;
Gabor, Franz ;
Viernstein, Helmut ;
Noe, Christian R. .
NEUROSCIENCE LETTERS, 2010, 469 (02) :224-228
[50]   PRESERVATION OF TRANSENDOTHELIAL GLUCOSE TRANSPORTER 1 AND P-GLYCOPROTEIN TRANSPORTERS IN A CORTICAL SLICE CULTURE MODEL OF THE BLOOD-BRAIN BARRIER [J].
Camenzind, R. S. ;
Chip, S. ;
Gutmann, H. ;
Kapfhammer, J. P. ;
Nitsch, C. ;
Bendfeldt, K. .
NEUROSCIENCE, 2010, 170 (01) :361-371